

**Karen Anthony PhD, FHEA, PgCert**  
Senior Lecturer in Molecular Bioscience  
Molecular Biosciences Research Group Lead



Postal address:  
Faculty of Health and Society  
University of Northampton  
University Drive  
Northampton  
NN1 5PH  
United Kingdom

Email: karen.anthony@northampton.ac.uk  
Phone: +44 (0) 1604 89 3467

## Biography

Karen studied biochemistry at the University of Leeds spending one year as a sandwich student at GlaxoSmithKline (GSK), Essex. At GSK Karen experienced the drug discovery process through performing large-scale purifications of protein drug targets. Developing a strong interest in neurodegeneration Karen joined the lab of Dr Jean-Marc Gallo at the Institute of Psychiatry, King's College London. Her PhD "tau RNA processing in neurodegeneration: *trans*-acting factors regulating alternative splicing and mRNA localisation" was awarded in 2009. As a post-doc in Dr Gallo's lab Karen established proof-of-concept for RNA reprogramming strategies including RNA *trans*-splicing therapies for spinocerebellar ataxia type 1 and the tauopathies. In 2010 Karen successfully translated her RNA expertise to the neuromuscular field and moved to the Dubowitz Neuromuscular Centre, Institute of Child Health, University College London (UCL). Working with Professor Francesco Muntoni, Karen played a key role in developing antisense oligonucleotide-mediated exon skipping as a therapeutic strategy for Duchenne muscular dystrophy (DMD). Her pre-clinical and clinical work in this area culminated in the first FDA-approved drug for DMD. In 2015 Karen attained a lectureship at the University of Northampton where she founded and leads the Molecular Biosciences Research Group. Her laboratory investigates the molecular mechanisms of neurological disorders with a focus on the neuropathophysiology of DMD. Karen also consults for international pharmaceutical and biotechnology companies on methodology for clinical trial biochemical outcome measures and the development of exon skipping therapies.

## Research outputs

### **A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures**

Hiller, M., Falzarano, M. S., Garcia-Jimenez, I., Sardone, V., Verheul, R. C., Popplewell, L., Anthony, K., Ruiz-Del-Yerro, E., Osman, H., Goeman, J. J., Mamchaoui, K., Dickson, G., Ferlini, A., Muntoni, F., Aartsma-Rus, A., Arechavala-Gomez, V., Datson, N. A. & Spitali, P., 2 Oct 2018, In : PLoS ONE. 13, 10, p. 1-15 15 p.

### **Neuropathophysiology of Duchenne muscular dystrophy: involvement of the dystrophin isoform Dp71 in cell migration and proliferation**

Ash, A., Machado, L., Raleigh, S. M. & Anthony, K., 1 Apr 2018, In : Neuromuscular Disorders. 28, Sup. 1

### **Brain involvement in Duchenne muscular dystrophy: a role for dystrophin isoform Dp71 in cell migration and proliferation**

Ash, A., Booth-Wynne, L. & Anthony, K., 2 Oct 2017, In : Neuromuscular Disorders. 27, Supp 2

### **Health and wellbeing amongst older people research in Northamptonshire**

Poole, H., Sixsmith, J., Parkes, J., Ward, A., Pyer, M., Campbell, J., Machado, L., Rehling, T., Youell, J., Carter, J., Oyebo, J., O'Malley, M., Anthony, K., Rogers, S., Jones, J., Siddons, L., Smith, L-A., Kay, T., Fraser, M., Score, J. & 8 others, El Khoury, L., Hameed, A., Albalbeisi, N., Durrant, L. G., Al-Zubaidi, R., Al-Rayahi, I., da Silva, K. & Taylor, J., 1 Aug 2017, In : East Midlands Research into Ageing Network (EMRAN) Discussion Paper Series. 15

### **A UV cross-linking method combined with infrared imaging to analyse RNA-protein interactions**

Malmqvist, T., Spickett, C., Gallo, J-M. & Anthony, K., 5 Jun 2017, In : Biology Methods & Protocols. 2, 1, p. 1-4 4 p., 1.

### **G.P.147 - Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant: implications for clinical trials**

Ricotti, V., Eagle, M., Butler, J., Decostre, V., Deborah, R., Moraux, A., Anthony, K., Sleby, V., Guglieri, M., Van der Holst, M., Jansen, M., Morgan, J., de Groot, I., Niks, E., Verschuuren, J., Servais, L., Hogrel, J. Y., Voit, T., Straub, V. & Muntoni, F., 1 Oct 2015, In : Neuromuscular Disorders. 25, Supp 2

**G.P.228 - Micro RNA profile associated with the dystrophin level in Becker muscular dystrophy**

Zaharieva, I., Cirak, S., Anthony, K., Feng, L., Tasca, G., Ferlini, A., Morgan, J. & Muntoni, F., 1 Oct 2015, In : Neuromuscular Disorders. 25, Supp 2

**Dystrophin quantification: biological and translational research implications**

Anthony, K., Arechavala-Gomez, V., Taylor, L. E., Vulin, A., Kaminoh, Y., Torelli, S., Feng, L., Janghra, N., Bonne, G., Beuvin, M., Barresi, R., Henderson, M., Laval, S., Loubakos, A., Campion, G., Straub, V., Voit, T., Sewry, C. A., Morgan, J. E., Flanigan, K. M. & 1 others, Muntoni, F., 25 Nov 2014, In : Neurology. 83, 22

**Tau mRNA is present in axonal RNA granules and is associated with elongation factor 1A**

Malmqvist, T., Anthony, K. & Gallo, J.-M., 10 Oct 2014, In : Brain Research. 1584, p. 22-27 6 p.

**Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to Exon 44 or 45 skipping**

Anthony, K., Arechavala-Gomez, V., Ricotti, V., Torelli, S., Feng, L., Janghra, N., Tasca, G., Guglieri, M., Barresi, R., Armaroli, A., Ferlini, A., Bushby, K., Straub, V., Ricci, E., Sewry, C., Morgan, J. & Muntoni, F., 1 Jan 2014, In : JAMA Neurology. 71, 1

**A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice**

Zhou, H., Janghra, N., Mitrpant, C., Dickinson, R. L., Anthony, K., Price, L., Eperon, I. C., Wilton, S. D., Morgan, J. & Muntoni, F., Mar 2013, In : Human Gene Therapy. p. 331-342 12 p.

**Assessing T cell-mediated immune response to dystrophin in the natural history of Duchenne muscular dystrophy**

Anthony, K., Ricotti, V., Guglieri, M., Servais, L., Voit, T., Bushby, K., Straub, V., Morgan, J. & Muntoni, F., 2013, In : Neuromuscular Disorders.

**Exon Skipping Quantification by Quantitative Reverse-Transcription Polymerase Chain Reaction in Duchenne Muscular Dystrophy Patients Treated with the Antisense Oligomer Eteplirsen**

Anthony, K., Feng, L., Arechavala-Gomez, V., Guglieri, M., Straub, V., Bushby, K., Cirak, S., Morgan, J. & Muntoni, F., Oct 2012, In : Human Gene Therapy Methods. p. 336-345 10 p.

**Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges**

Arechavala-Gomez, V., Anthony, K., Morgan, J. & Muntoni, F., 1 Jun 2012, In : Current Gene Therapy. p. 152-160 9 p.

**Exon-skipping therapy for Duchenne muscular dystrophy - Authors' reply**

Arechavala-Gomez, V., Cirak, S., Anthony, K., Morgan, J. & Muntoni, F., 14 Jan 2012, In : The Lancet.

**A morpholino antisense oligonucleotide rescues type I and type III SMA mice**

Zhou, H., Janghra, N., Anthony, K., Morgan, J. & Muntoni, F., 2012, In : Neuromuscular Disorders.

**Biochemical and clinical variability of Becker muscular dystrophy: Predicting optimal target exons for exon skipping therapy in Duchenne muscular**

Anthony, K., Arechavala-Gomez, V., Ricotti, V., Torelli, S., Feng, L., Tasca, G., Guglieri, M., Barresi, R., Armaroli, A., Ferlini, A., Bushby, K., Straub, V., Ricci, E., Sewry, C., Morgan, J. & Muntoni, F., 2012, In : Neuromuscular Disorders.

**Correlation of internally deleted dystrophin and dystrophin-associated protein expression with clinical severity in Becker muscular dystrophy**

Anthony, K., Cirak, S., Torelli, S., Tasca, G., Feng, L., Arechavala-Gomez, V., Armaroli, A., Guglieri, M., Straathof, C. S., Verschuuren, J. J., Aartsma-Rus, A., Helderma-Van Den Enden, P., Bushby, K., Straub, V., Sewry, C., Ferlini, A., Ricci, E., Morgan, J. & Muntoni, F., 2012, In : Neuromuscular Disorders.

**Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in duchenne muscular dystrophy**

Cirak, S., Feng, L., Anthony, K., Arechavala-Gomez, V., Torelli, S., Sewry, C., Morgan, J. E. & Muntoni, F., 2012, In : Molecular Therapy. p. 462-467 6 p.

**Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study**

Cirak, S., Arechavala-Gomez, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., Dickson, G., Wood, M. J., Wilton, S. D., Straub, V., Kole, R., Shrewsbury, S. B., Sewry, C., Morgan, J. E., Bushby, K. & Muntoni, F., 13 Aug 2011, In : The Lancet. p. 595-605 11 p.

**A TaqMan qRT-PCR assay to assess patient response in exon skipping clinical trials for Duchenne muscular dystrophy**

Anthony, K., Feng, L., Arechavala-Gomez, V., Morgan, J. & Muntoni, F., 2011.

**Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials**

Anthony, K., Cirak, S., Torelli, S., Tasca, G., Feng, L., Arechavala-Gomez, V., Armaroli, A., Guglieri, M., Straathof, C. S., Verschuuren, J. J., Aartsma-Rus, A., Helderma-Van Den Eenden, P., Bushby, K., Straub, V., Sewry, C., Ferlini, A., Ricci, E., Morgan, J. E. & Muntoni, F., 2011, In : Brain. p. 3544-3556 13 p.

**Exon skipping and dystrophin restoration in Duchenne muscular dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment**

Cirak, S., Arechavala-Gomez, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Garralda, M. E., Wells, D. J., Dickson, G., Wood, M. J., Wilton, S. D., Straub, V., Shrewsbury, S. B., Sewry, C., Morgan, J., Bushby, K. & Muntoni, F., 2011, In : Neuromuscular Disorders.

**P07 The feasibility of exon skipping to restore the reading frame in DMD patients with duplications**

Kim, J., Anthony, K., Cloke, V., Yau, M., Abbs, S., Morgan, J. & Muntoni, F., 2011, In : Neuromuscular Disorders.

**Quantification of exon skipping in Duchenne muscular dystrophy by qRT-PCR**

Anthony, K., Morgan, J. & Muntoni, F., 2011, In : Neuromuscular Disorders.

**Aberrant RNA processing events in neurological disorders**

Anthony, K. & Gallo, J. M., 18 Jun 2010, In : Brain Research. p. 67-77 11 p.

**Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing**

Rodriguez-Martin, T., Anthony, K., Garcia-Blanco, M. A., Mansfield, S. G., Anderton, B. H. & Gallo, J. M., 2009, In : Human Molecular Genetics. p. 3266-3273 8 p.

**Expression, localization and tau exon 10 splicing activity of the brain RNA-binding protein TNRC4**

Chapple, P. J., Anthony, K., Martin, T. R., Dev, A., Cooper, T. A. & Gallo, J. M., 15 Nov 2007, In : Human Molecular Genetics. p. 2760-2769 10 p.

**Characterization of the Neuronal RNA-binding Protein CELF3, a Modulator of Tau Exon 10 Alternative Splicing**

Chapple, P. J., Rodriguez-Martin, T., Anthony, K., Cooper, T. A. & Gallo, J.-M., 2007.

**Identification of regulators of tau mRNA localisation**

Anthony, K., Chapple, P. J. & Gallo, J.-M., 2007.